The 4-8-fold antigen-sparing adjuvanted pandemic influenza vaccine demonstrated superior and clinically important prevention of A ( H1N1 ) pdm09 infection , compared with nonadjuvanted vaccine , with no observed increase in medically attended or serious adverse events .